JPWO2019169212A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019169212A5 JPWO2019169212A5 JP2020545621A JP2020545621A JPWO2019169212A5 JP WO2019169212 A5 JPWO2019169212 A5 JP WO2019169212A5 JP 2020545621 A JP2020545621 A JP 2020545621A JP 2020545621 A JP2020545621 A JP 2020545621A JP WO2019169212 A5 JPWO2019169212 A5 JP WO2019169212A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- binding fragment
- seq
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims description 104
- 102000038129 antigens Human genes 0.000 claims description 104
- 108091007172 antigens Proteins 0.000 claims description 104
- 102000004965 antibodies Human genes 0.000 claims description 101
- 108090001123 antibodies Proteins 0.000 claims description 101
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 40
- 229920000023 polynucleotide Polymers 0.000 claims description 20
- 239000002157 polynucleotide Substances 0.000 claims description 20
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 16
- 230000001225 therapeutic Effects 0.000 claims description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 13
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 210000004027 cells Anatomy 0.000 claims description 11
- 238000001514 detection method Methods 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 8
- 238000003364 immunohistochemistry Methods 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-Diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 claims description 4
- 238000002965 ELISA Methods 0.000 claims description 4
- 230000035693 Fab Effects 0.000 claims description 4
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims description 4
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims description 4
- NFGXHKASABOEEW-UHFFFAOYSA-N (+)-methoprene Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 210000000170 Cell Membrane Anatomy 0.000 claims description 2
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims description 2
- 208000006402 Ductal Carcinoma Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 108010070144 Single-Chain Antibodies Proteins 0.000 claims description 2
- 102000005632 Single-Chain Antibodies Human genes 0.000 claims description 2
- 206010041823 Squamous cell carcinoma Diseases 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 238000004166 bioassay Methods 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 230000001086 cytosolic Effects 0.000 claims description 2
- 230000001809 detectable Effects 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010003445 Ascites Diseases 0.000 description 1
- 210000002751 Lymph Anatomy 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
Description
他の実施形態は以下のクレームの範囲内にある。
特定の実施形態では、例えば以下の項目が提供される。
（項目１）
ヒトＢ７－Ｈ４に特異的に結合する単離された抗体またはその抗原結合断片であって、配列番号２２のアミノ酸配列を含む重鎖可変領域（ＶＨ）相補性決定領域（ＣＤＲ）１と、配列番号２３のアミノ酸配列を含むＶＨ ＣＤＲ２と、配列番号２４のアミノ酸配列を含むＶＨ ＣＤＲ３と、配列番号２５のアミノ酸配列を含む軽鎖可変領域（ＶＬ）ＣＤＲ１と、配列番号２６、２７または２８のアミノ酸配列を含むＶＬ ＣＤＲ２と、配列番号２９のアミノ酸配列を含むＶＬ ＣＤＲ３とを含む、前記抗体またはその抗原結合断片。
（項目２）
前記抗体またはその抗原結合断片が、配列番号６、７または８のアミノ酸配列を含むＶＨを含む、項目１に記載の抗体またはその抗原結合断片。
（項目３）
前記抗体またはその抗原結合断片が、配列番号９、１０または１１のアミノ酸配列を含むＶＬを含む、項目１または２に記載の抗体またはその抗原結合断片。
（項目４）
ヒトＢ７－Ｈ４に特異的に結合する単離された抗体またはその抗原結合断片であって、前記抗体またはその抗原結合断片が重鎖可変領域及び軽鎖可変領域を含み、前記重鎖可変領域が配列番号６、７または８のアミノ酸配列を含む、前記抗体またはその抗原結合断片。
（項目５）
ヒトＢ７－Ｈ４に特異的に結合する単離された抗体またはその抗原結合断片であって、前記抗体が重鎖可変領域及び軽鎖可変領域を含み、前記軽鎖可変領域が配列番号９、１０または１１のアミノ酸配列を含む、前記抗体またはその抗原結合断片。
（項目６）
ヒトＢ７－Ｈ４に特異的に結合する単離された抗体またはその抗原結合断片であって、（ａ）それぞれ配列番号６及び９；
（ｂ）それぞれ配列番号６及び１０；
（ｃ）それぞれ配列番号６及び１１；
（ｄ）それぞれ配列番号７及び９；
（ｅ）それぞれ配列番号７及び１０；
（ｆ）それぞれ配列番号７及び１１；
（ｇ）それぞれ配列番号８及び９；
（ｈ）それぞれ配列番号８及び１０；または
（ｉ）それぞれ配列番号８及び１１のアミノ酸配列を含む重鎖可変領域及び軽鎖可変領域を含む、前記抗体またはその抗原結合断片。
（項目７）
前記抗体またはその抗原結合断片がさらに重鎖定常領域を含む、項目１～６のいずれか１項に記載の抗体またはその抗原結合断片。
（項目８）
前記重鎖定常領域がマウスＩｇＧ
１
またはＩｇＧ
２ａ
の重鎖定常領域である、項目７に記載の抗体またはその抗原結合断片。
（項目９）
前記抗体または抗原結合断片がさらに軽鎖定常領域を含む、項目１～８のいずれか１項に記載の抗体またはその抗原結合断片。
（項目１０）
前記軽鎖定常領域がマウスＩｇＧκ軽鎖定常領域である、項目９に記載の抗体またはその抗原結合断片。
（項目１１）
前記抗体またはその抗原結合断片が配列番号１６、１７、１８、８９、９０または９１のアミノ酸配列を含む重鎖を含む、項目１～６のいずれか１項に記載の抗体またはその抗原結合断片。
（項目１２）
前記抗体またはその抗原結合断片が配列番号１９、３０または３１のアミノ酸配列を含む軽鎖を含む、項目１～６または１１のいずれか１項に記載の抗体またはその抗原結合断片。
（項目１３）
前記抗体または抗原結合断片が、
（ａ）それぞれ配列番号１６及び１９；
（ｂ）それぞれ配列番号１６及び３０；
（ｃ）それぞれ配列番号１６及び３１；
（ｄ）それぞれ配列番号１７及び１９；
（ｅ）それぞれ配列番号１７及び３０；
（ｆ）それぞれ配列番号１７及び３１；
（ｇ）それぞれ配列番号１８及び１９；
（ｈ）それぞれ配列番号１８及び３０；
（ｉ）それぞれ配列番号１８及び３１；
（ｊ）それぞれ配列番号８９及び１９；
（ｋ）それぞれ配列番号９０及び１９；または
（ｌ）それぞれ配列番号９１及び１９のアミノ酸配列を含む重鎖及び軽鎖を含む、項目１～６のいずれか１項に記載の抗体またはその抗原結合断片。
（項目１４）
ヒトＢ７－Ｈ４に特異的に結合する単離された抗体またはその抗原結合断片であって、前記抗体またはその抗原結合断片が、Ｊ５１２、Ｊ５１３、Ｊ５１４、Ｊ５１５、Ｊ５１６、Ｊ５１７、Ｊ５１８、Ｊ５１９、Ｊ５２０、Ｊ５２１、及びＪ５２２から成る群から選択される抗体のＶＨ ＣＤＲ１、ＶＨ ＣＤＲ２、ＶＨ ＣＤＲ３、ＶＬ ＣＤＲ１、ＶＬ ＣＤＲ２、及びＶＬ ＣＤＲ３を含む、前記抗体またはその抗原結合断片。
（項目１５）
前記ＣＤＲがＫａｂａｔが定義したＣＤＲ、Ｃｈｏｔｈｉａが定義したＣＤＲ、またはＡｂＭの定義のＣＤＲである、項目１４に記載の抗体またはその抗原結合断片。
（項目１６）
項目１～１５のいずれか１項に記載の抗体またはその抗原結合断片と同じヒトＢ７－Ｈ４のエピトープに特異的に結合する、単離された抗体またはその抗原結合断片。
（項目１７）
項目１～１５のいずれか１項に記載の抗体またはその抗原結合断片のヒトＢ７－Ｈ４への結合を 競合して阻害する、単離された抗体またはその抗原結合断片。
（項目１８）
前記抗体またはその抗原結合断片がマウスの抗体またはその抗原結合断片である、項目１～１７のいずれか１項に記載の抗体またはその抗原結合断片。
（項目１９）
完全長抗体である、項目１～１８のいずれか１項に記載の抗体またはその抗原結合断片。
（項目２０）
抗原結合断片である、項目１～１８のいずれか１項に記載の抗体またはその抗原結合断片。
（項目２１）
前記抗原結合断片が、Ｆａｂ、Ｆａｂ’、Ｆ（ａｂ’）
２
、単鎖Ｆｖ（ｓｃＦｖ）、ジスルフィド結合Ｆｖ、ミニボディ、Ｆ（ａｂ’）
３
、ダイアボディ、（ｓｃＦｖ）
２
、またはｓｃＦｖ－Ｆｃを含む、項目２０に記載の抗原結合断片。
（項目２２）
さらに、検出可能な標識を含む、項目１～２１のいずれか１項に記載の抗体またはその抗原結合断片。
（項目２３）
項目１～２２のいずれか１項に記載の抗体またはその抗原結合断片の重鎖可変領域または重鎖をコードする核酸分子を含む、単離されたポリヌクレオチド。
（項目２４）
前記核酸分子が配列番号６、７もしくは８のＶＨをコードする、または配列番号１６、１７もしくは１８の重鎖をコードする項目２３に記載の単離されたポリヌクレオチド。
（項目２５）
前記核酸分子が配列番号１２、１３、１４、９３、９４または９５の配列を含む、項目２４に記載の単離されたポリヌクレオチド。
（項目２６）
項目１～２２のいずれか１項に記載の抗体またはその抗原結合断片の軽鎖可変領域または軽鎖をコードする核酸分子を含む、単離されたポリヌクレオチド。
（項目２７）
前記核酸分子が配列番号９、１０もしくは１１のＶＬをコードする、または配列番号１９、３０もしくは３１の軽鎖をコードする、項目２６に記載の単離されたポリヌクレオチド。
（項目２８）
前記核酸分子が配列番号１５、９６または９７の配列を含む、項目２７に記載の単離されたポリヌクレオチド。
（項目２９）
項目１～２２のいずれか１項に記載の抗体またはその抗原結合断片の重鎖可変領域または重鎖と、項目１～２２のいずれか１項に記載の抗体またはその抗原結合断片の軽鎖可変領域または軽鎖とをコードする核酸分子を含む、単離されたポリヌクレオチド。
（項目３０）
項目２３～２９のいずれか１項に記載のポリヌクレオチドを含む、単離されたベクター。
（項目３１）
項目２３～２９のいずれか１項に記載のポリヌクレオチド、項目３０に記載のベクター、または項目２３～２５のいずれか１項に記載のポリヌクレオチドを含む第１のベクターと項目２６～２８のいずれか１項に記載のポリヌクレオチドを含む第２のベクターを含む、宿主細胞。
（項目３２）
ＣＨＯ細胞またはＨＥＫ細胞である、項目３１に記載の宿主細胞。
（項目３３）
ヒトＢ７－Ｈ４に特異的に結合する抗体またはその抗原結合断片を産生させる方法であって、前記核酸分子が発現され、前記抗体またはその抗原結合断片が産生されるように項目３１または３２に記載の宿主細胞を培養することを含む、前記方法。
（項目３４）
ヒトＢ７－Ｈ４に特異的に結合し、且つ項目２３～２９のいずれか１項に記載のポリヌクレオチドによってコードされる、単離された抗体またはその抗原結合断片。
（項目３５）
試料にてＢ７－Ｈ４を検出する方法であって、前記試料を項目１～２２または３４のいずれか１項に記載の抗体またはその抗原結合断片と接触させることを含み、任意で、前記方法はさらに、前記抗体またはその抗原結合断片のＢ７－Ｈ４に対する結合を検出することを含む、前記方法。
（項目３６）
前記試料が対象におけるがんから得られる項目３５に記載の方法。
（項目３７）
Ｂ７－Ｈ４が検出された後、治療用の抗Ｂ７－Ｈ４抗体またはその抗原結合断片を前記対象に投与することをさらに含む、項目３６に記載の方法。
（項目３８）
対象にてＢ７－Ｈ４を発現するがんを治療する方法であって、前記方法が治療用の抗Ｂ７－Ｈ４抗体またはその抗原結合断片を前記対象に投与することを含み、その際、Ｂ７－Ｈ４の発現が、前記対象から得られた試料にて項目１～２１または３３のいずれか１項に記載の抗体またはその抗原結合断片を用いて検出された、前記方法。
（項目３９）
前記がんから得られた前記試料にて前記Ｂ７－Ｈ４を検出することをさらに含む、項目３８に記載の方法。
（項目４０）
前記検出されたＢ７－Ｈ４が細胞膜Ｂ７－Ｈ４である、項目３５～３９のいずれか１項に記載の方法。
（項目４１）
前記検出されたＢ７－Ｈ４が細胞質Ｂ７－Ｈ４である、項目３５～３９のいずれか１項に記載の方法。
（項目４２）
Ｂ７－Ｈ４が細胞全体において検出される、項目３５～３９のいずれか１項に記載の方法。
（項目４３）
前記Ｂ７－Ｈ４が循環腫瘍細胞で検出される、項目３５～４２のいずれか１項に記載の方法。
（項目４４）
前記試料が、対象に由来する固形組織、生検、腹水、血漿、血清、リンパ液、または腫瘍である、項目３５～４３のいずれか１項に記載の方法。
（項目４５）
前記がんが、乳癌、乳管癌、子宮内膜癌、卵巣癌、非小細胞肺癌、膵臓癌、甲状腺癌、腎臓癌及び膀胱癌から成る群から選択される、項目３６～４４のいずれか１項に記載の方法。
（項目４６）
前記乳癌がトリプルネガティブ乳癌であり、または前記非小細胞肺癌が扁平上皮癌である、項目４５に記載の方法。
（項目４７）
前記検出方法が、酵素結合免疫吸着アッセイ（ＥＬＩＳＡ）、蛍光活性化細胞選別（ＦＡＣＳ）アッセイ、または免疫組織化学（ＩＨＣ）を使用する、項目３５～４６のいずれか１項に記載の方法。
（項目４８）
前記検出方法がＩＨＣを使用し、項目１～２１または３４のいずれか１項に記載の抗体またはその抗原結合断片の濃度が約１～約５０μｇ／ｍＬである、項目４７に記載の方法。
（項目４９）
前記抗体またはその抗原結合断片の濃度が約１～約２０μｇ／ｍＬである、項目４８に記載の方法。
（項目５０）
前記抗体またはその抗原結合断片の濃度が約１０μｇ／ｍＬである、項目４９に記載の方法。
（項目５１）
前記検出方法がＩＨＣを使用し、３，３’－ジアミノベンジジン（ＤＡＢ）が検出に使用される、項目４７～５０のいずれか１項に記載の方法。
（項目５２）
前記対象がヒトである、項目３６～５１のいずれか１項に記載の方法。
（項目５３）
項目１～２１または３４のいずれか１項に記載の抗体またはその抗原結合断片と、（ａ）検出試薬、（ｂ）Ｂ７－Ｈ４抗原、（ｃ）治療用抗Ｂ７－Ｈ４抗体、または（ｄ）（ｃ）（ａ）～（ｃ）の組み合わせのいずれかとを含む、キット。
（項目５４）
前記治療用の抗体または抗原結合断片が、２０５０２または２２２１３のＶＨ ＣＤＲ１、ＶＨ ＣＤＲ２、ＶＨ ＣＤＲ３、ＶＬ ＣＤＲ１、ＶＬ ＣＤＲ２、及びＶＬ ＣＤＲ３を含む、項目３７～５３のいずれか１項に記載の方法またはキット。
（項目５５）
前記ＣＤＲが、Ｋａｂａｔが定義したＣＤＲ、Ｃｈｏｔｈｉａが定義したＣＤＲ、またはＡｂＭの定義のＣＤＲである項目５４に記載の方法またはキット。
（項目５６）
前記ＶＨ ＣＤＲ１、ＶＨ ＣＤＲ２、ＶＨ ＣＤＲ３、ＶＬ ＣＤＲ１、ＶＬ ＣＤＲ２、及びＶＬ ＣＤＲ３が、それぞれ配列番号３２～３７のアミノ酸配列、またはそれぞれ配列番号５８～６３のアミノ酸配列を含む、項目５５に記載の方法またはキット。
（項目５７）
前記治療用の抗体または抗原結合断片が、重鎖可変領域及び軽鎖可変領域を含み、前記重鎖可変領域が配列番号５４または配列番号６４のアミノ酸配列を含む、項目３７～５６のいずれか１項に記載の方法またはキット。
（項目５８）
前記治療用の抗体または抗原結合断片が、重鎖可変領域及び軽鎖可変領域を含み、前記軽鎖可変領域が配列番号５５または配列番号６５のアミノ酸配列を含む、項目３７～５６のいずれか１項に記載の方法またはキット。
（項目５９）
前記治療用の抗体または抗原結合断片が、（ｉ）配列番号５４のアミノ酸配列を含む重鎖可変領域及び配列番号５５のアミノ酸配列を含む軽鎖可変領域を含む、または（ｉｉ）配列番号６４のアミノ酸配列を含む重鎖可変領域及び配列番号６５のアミノ酸配列を含む軽鎖可変領域を含む、項目３７～５６のいずれか１項に記載の方法またはキット。
（項目６０）
前記治療用の抗体またはその抗原結合断片が、配列番号５６または配列番号７４のアミノ酸配列を含む重鎖を含む、項目３７～５６のいずれか１項に記載の方法またはキット。
（項目６１）
前記治療用の抗体またはその抗原結合断片が、配列番号５７または配列番号７５のアミノ酸配列を含む軽鎖を含む、項目３７～５６のいずれか１項に記載の方法またはキット。
（項目６２）
前記治療用の抗体またはその抗原結合断片が（ｉ）配列番号５６のアミノ酸配列を含む重鎖及び配列番号５７のアミノ酸配列を含む軽鎖を含む、または（ｉｉ）配列番号７４のアミノ酸配列を含む重鎖及び配列番号７５のアミノ酸配列を含む軽鎖を含む、項目３７～５６のいずれか１項に記載の方法またはキット。
Other embodiments are within the scope of the following claims.
In certain embodiments, for example, the following items are provided.
(Item 1)
An isolated antibody or antigen-binding fragment thereof that specifically binds to human B7-H4, the heavy chain variable region (VH) complementarity determining region (CDR) 1 containing the amino acid sequence of SEQ ID NO: 22, and the sequence. VH CDR2 containing the amino acid sequence of SEQ ID NO: 23, VH CDR3 containing the amino acid sequence of SEQ ID NO: 24, light chain variable region (VL) CDR1 containing the amino acid sequence of SEQ ID NO: 25, and amino acids of SEQ ID NO: 26, 27 or 28. The antibody or antigen-binding fragment thereof comprising VL CDR2 comprising a sequence and VL CDR3 comprising the amino acid sequence of SEQ ID NO: 29.
(Item 2)
The antibody or antigen-binding fragment thereof according to item 1, wherein the antibody or antigen-binding fragment thereof comprises VH containing the amino acid sequence of SEQ ID NO: 6, 7 or 8.
(Item 3)
The antibody or antigen-binding fragment thereof according to item 1 or 2, wherein the antibody or antigen-binding fragment thereof comprises VL containing the amino acid sequence of SEQ ID NO: 9, 10 or 11.
(Item 4)
An isolated antibody or antigen-binding fragment thereof that specifically binds to human B7-H4, wherein the antibody or antigen-binding fragment thereof contains a heavy chain variable region and a light chain variable region, and the heavy chain variable region is contained. The antibody or antigen-binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 6, 7 or 8.
(Item 5)
An isolated antibody or antigen-binding fragment thereof that specifically binds to human B7-H4, wherein the antibody comprises a heavy chain variable region and a light chain variable region, and the light chain variable region is SEQ ID NO: 9, 10 Or the antibody or antigen-binding fragment thereof comprising 11 amino acid sequences.
(Item 6)
An isolated antibody or antigen-binding fragment thereof that specifically binds to human B7-H4, (a) SEQ ID NOs: 6 and 9, respectively;
(B) SEQ ID NOs: 6 and 10, respectively;
(C) SEQ ID NOs: 6 and 11;
(D) SEQ ID NOs: 7 and 9, respectively;
(E) SEQ ID NOs: 7 and 10, respectively;
(F) SEQ ID NOs: 7 and 11, respectively;
(G) SEQ ID NOs: 8 and 9, respectively;
(H) SEQ ID NOs: 8 and 10; or
(I) The antibody or antigen-binding fragment thereof, which comprises a heavy chain variable region and a light chain variable region containing the amino acid sequences of SEQ ID NOs: 8 and 11, respectively.
(Item 7)
Item 6. The antibody or antigen-binding fragment thereof according to any one of Items 1 to 6, wherein the antibody or antigen-binding fragment thereof further contains a heavy chain constant region.
(Item 8)
Item 7. The antibody or antigen-binding fragment thereof according to item 7, wherein the heavy chain constant region is a heavy chain constant region of mouse IgG 1 or IgG 2a .
(Item 9)
Item 6. The antibody or antigen-binding fragment thereof according to any one of Items 1 to 8, wherein the antibody or antigen-binding fragment further comprises a light chain constant region.
(Item 10)
Item 9. The antibody or antigen-binding fragment thereof according to Item 9, wherein the light chain constant region is a mouse IgGκ light chain constant region.
(Item 11)
Item 6. The antibody or antigen-binding fragment thereof according to any one of Items 1 to 6, wherein the antibody or an antigen-binding fragment thereof comprises a heavy chain containing the amino acid sequence of SEQ ID NO: 16, 17, 18, 89, 90 or 91.
(Item 12)
Item 6. The antibody or antigen-binding fragment thereof according to any one of Items 1 to 6 or 11, wherein the antibody or antigen-binding fragment thereof comprises a light chain comprising the amino acid sequence of SEQ ID NO: 19, 30 or 31.
(Item 13)
The antibody or antigen-binding fragment
(A) SEQ ID NOs: 16 and 19;
(B) SEQ ID NOs: 16 and 30, respectively;
(C) SEQ ID NOs: 16 and 31, respectively;
(D) SEQ ID NOs: 17 and 19, respectively;
(E) SEQ ID NOs: 17 and 30, respectively;
(F) SEQ ID NOs: 17 and 31, respectively;
(G) SEQ ID NOs: 18 and 19, respectively;
(H) SEQ ID NOs: 18 and 30, respectively;
(I) SEQ ID NOs: 18 and 31, respectively;
(J) SEQ ID NOs: 89 and 19;
(K) SEQ ID NOs: 90 and 19; or
(L) The antibody or antigen-binding fragment thereof according to any one of Items 1 to 6, which comprises a heavy chain and a light chain containing the amino acid sequences of SEQ ID NOs: 91 and 19, respectively.
(Item 14)
An isolated antibody or antigen-binding fragment thereof that specifically binds to human B7-H4, wherein the antibody or antigen-binding fragment thereof is J512, J513, J514, J515, J516, J517, J518, J518, J520. , J521, and an antigen-binding fragment thereof comprising VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 of an antibody selected from the group consisting of J522.
(Item 15)
The antibody or antigen-binding fragment thereof according to item 14, wherein the CDR is a CDR defined by Kabat, a CDR defined by Chothia, or a CDR defined by AbM.
(Item 16)
An isolated antibody or antigen-binding fragment thereof that specifically binds to the same epitope of human B7-H4 as the antibody or antigen-binding fragment thereof according to any one of items 1 to 15.
(Item 17)
An isolated antibody or antigen-binding fragment thereof that competitively inhibits the binding of the antibody or antigen-binding fragment thereof according to any one of items 1 to 15 to human B7-H4.
(Item 18)
Item 6. The antibody or antigen-binding fragment thereof according to any one of Items 1 to 17, wherein the antibody or antigen-binding fragment thereof is a mouse antibody or antigen-binding fragment thereof.
(Item 19)
The antibody or antigen-binding fragment thereof according to any one of items 1 to 18, which is a full-length antibody.
(Item 20)
Item 6. The antibody according to any one of Items 1 to 18, which is an antigen-binding fragment, or an antigen-binding fragment thereof.
(Item 21)
The antigen-binding fragment is Fab, Fab', F (ab') 2 , single chain Fv (scFv), disulfide bond Fv, minibody, F (ab') 3 , diabodies, (scFv) 2 , or scFv-. The antigen-binding fragment according to item 20, which comprises Fc.
(Item 22)
The antibody or antigen-binding fragment thereof according to any one of items 1 to 21, further comprising a detectable label.
(Item 23)
An isolated polynucleotide comprising a heavy chain variable region or a nucleic acid molecule encoding a heavy chain of the antibody according to any one of items 1 to 22 or an antigen-binding fragment thereof.
(Item 24)
23. The isolated polynucleotide according to item 23, wherein the nucleic acid molecule encodes a VH of SEQ ID NO: 6, 7 or 8 or encodes a heavy chain of SEQ ID NO: 16, 17 or 18.
(Item 25)
24. The isolated polynucleotide according to item 24, wherein the nucleic acid molecule comprises the sequence of SEQ ID NO: 12, 13, 14, 93, 94 or 95.
(Item 26)
An isolated polynucleotide comprising a light chain variable region or a nucleic acid molecule encoding a light chain of the antibody according to any one of items 1 to 22 or an antigen-binding fragment thereof.
(Item 27)
26. The isolated polynucleotide according to item 26, wherein the nucleic acid molecule encodes the VL of SEQ ID NO: 9, 10 or 11 or the light chain of SEQ ID NO: 19, 30 or 31.
(Item 28)
27. The isolated polynucleotide according to item 27, wherein the nucleic acid molecule comprises the sequence of SEQ ID NO: 15, 96 or 97.
(Item 29)
The heavy chain variable region or heavy chain of the antibody or antigen-binding fragment thereof according to any one of items 1 to 22, and the light chain variable of the antibody or antigen-binding fragment thereof according to any one of items 1 to 22. An isolated polynucleotide comprising a nucleic acid molecule encoding a region or a light chain.
(Item 30)
An isolated vector comprising the polynucleotide according to any one of items 23 to 29.
(Item 31)
The polynucleotide according to any one of items 23 to 29, the vector according to item 30, or the first vector containing the polynucleotide according to any one of items 23 to 25 and any of items 26 to 28. A host cell comprising a second vector comprising the polynucleotide according to item 1.
(Item 32)
31. The host cell according to item 31, which is a CHO cell or a HEK cell.
(Item 33)
Item 31 or 32, wherein the method for producing an antibody or an antigen-binding fragment thereof that specifically binds to human B7-H4 is such that the nucleic acid molecule is expressed and the antibody or the antigen-binding fragment thereof is produced. The method comprising culturing a host cell of the above.
(Item 34)
An isolated antibody or antigen-binding fragment thereof that specifically binds to human B7-H4 and is encoded by the polynucleotide according to any one of items 23 to 29.
(Item 35)
A method for detecting B7-H4 in a sample, comprising contacting the sample with the antibody or antigen-binding fragment thereof according to any one of items 1 to 22 or 34, optionally said the method. The method further comprises detecting the binding of the antibody or antigen-binding fragment thereof to B7-H4.
(Item 36)
35. The method of item 35, wherein the sample is obtained from cancer in a subject.
(Item 37)
36. The method of item 36, further comprising administering to the subject a therapeutic anti-B7-H4 antibody or antigen-binding fragment thereof after B7-H4 is detected.
(Item 38)
A method of treating a cancer expressing B7-H4 in a subject, wherein the method comprises administering to the subject a therapeutic anti-B7-H4 antibody or antigen-binding fragment thereof, in which case B7- The method as described above, wherein expression of H4 was detected in a sample obtained from the subject using the antibody according to any one of items 1 to 21 or 33 or an antigen-binding fragment thereof.
(Item 39)
38. The method of item 38, further comprising detecting the B7-H4 in the sample obtained from the cancer.
(Item 40)
The method according to any one of items 35 to 39, wherein the detected B7-H4 is a cell membrane B7-H4.
(Item 41)
The method according to any one of items 35 to 39, wherein the detected B7-H4 is cytoplasmic B7-H4.
(Item 42)
The method according to any one of items 35 to 39, wherein B7-H4 is detected in the whole cell.
(Item 43)
The method according to any one of items 35 to 42, wherein the B7-H4 is detected in circulating tumor cells.
(Item 44)
The method according to any one of items 35 to 43, wherein the sample is a solid tissue, biopsy, ascites, plasma, serum, lymph, or tumor derived from the subject.
(Item 45)
Any of items 36 to 44, wherein the cancer is selected from the group consisting of breast cancer, ductal carcinoma, endometrial cancer, ovarian cancer, non-small cell lung cancer, pancreatic cancer, thyroid cancer, kidney cancer and bladder cancer. The method according to item 1.
(Item 46)
45. The method of item 45, wherein the breast cancer is triple negative breast cancer or the non-small cell lung cancer is squamous cell carcinoma.
(Item 47)
Item 6. The method according to any one of items 35 to 46, wherein the detection method uses an enzyme-linked immunosorbent assay (ELISA), a fluorescence activated cell selection (FACS) assay, or immunohistochemistry (IHC).
(Item 48)
47. The method of item 47, wherein the detection method uses IHC and the concentration of the antibody or antigen-binding fragment thereof according to any one of items 1 to 21 or 34 is about 1 to about 50 μg / mL.
(Item 49)
48. The method of item 48, wherein the concentration of the antibody or antigen-binding fragment thereof is from about 1 to about 20 μg / mL.
(Item 50)
49. The method of item 49, wherein the concentration of the antibody or antigen-binding fragment thereof is about 10 μg / mL.
(Item 51)
The method according to any one of items 47 to 50, wherein the detection method uses IHC and 3,3'-diaminobenzidine (DAB) is used for detection.
(Item 52)
The method according to any one of items 36 to 51, wherein the subject is a human.
(Item 53)
The antibody or antigen-binding fragment thereof according to any one of items 1 to 21 or 34, and (a) detection reagent, (b) B7-H4 antigen, (c) therapeutic anti-B7-H4 antibody, or (d). ) (C) A kit comprising any of the combinations (a) to (c).
(Item 54)
38. The method of any one of items 37-53, wherein the therapeutic antibody or antigen binding fragment comprises 20502 or 22213 VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. kit.
(Item 55)
54. The method or kit of item 54, wherein the CDR is a Kabat-defined CDR, a Chothia-defined CDR, or an AbM-defined CDR.
(Item 56)
55. The method of item 55, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 each contain the amino acid sequences of SEQ ID NOs: 32 to 37, or the amino acid sequences of SEQ ID NOs: 58 to 63, respectively. Or a kit.
(Item 57)
One of items 37-56, wherein the therapeutic antibody or antigen binding fragment comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 54 or SEQ ID NO: 64. The method or kit described in the section.
(Item 58)
One of items 37-56, wherein the therapeutic antibody or antigen binding fragment comprises a heavy chain variable region and a light chain variable region, wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 55 or SEQ ID NO: 65. The method or kit described in the section.
(Item 59)
The therapeutic antibody or antigen binding fragment comprises (i) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 54 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 55, or (ii) of SEQ ID NO: 64. The method or kit according to any one of items 37 to 56, comprising a heavy chain variable region comprising an amino acid sequence and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 65.
(Item 60)
37. The method or kit of item 37-56, wherein the therapeutic antibody or antigen binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 56 or SEQ ID NO: 74.
(Item 61)
37. The method or kit of any one of items 37-56, wherein the therapeutic antibody or antigen binding fragment thereof comprises a light chain comprising the amino acid sequence of SEQ ID NO: 57 or SEQ ID NO: 75.
(Item 62)
The therapeutic antibody or antigen-binding fragment thereof comprises (i) a heavy chain comprising the amino acid sequence of SEQ ID NO: 56 and a light chain comprising the amino acid sequence of SEQ ID NO: 57, or (ii) comprising the amino acid sequence of SEQ ID NO: 74. 37. The method or kit of any one of items 37-56, comprising a heavy chain and a light chain comprising the amino acid sequence of SEQ ID NO: 75.
Claims (28)
（ａ）それぞれ配列番号６及び９；
（ｂ）それぞれ配列番号６及び１０；
（ｃ）それぞれ配列番号６及び１１；
（ｄ）それぞれ配列番号７及び９；
（ｅ）それぞれ配列番号７及び１０；
（ｆ）それぞれ配列番号７及び１１；
（ｇ）それぞれ配列番号８及び９；
（ｈ）それぞれ配列番号８及び１０；または
（ｉ）それぞれ配列番号８及び１１のアミノ酸配列を含む重鎖可変領域及び軽鎖可変領域を含む、前記抗体またはその抗原結合断片。 An isolated antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.
(A) SEQ ID NOs: 6 and 9, respectively;
(B) SEQ ID NOs: 6 and 10, respectively;
(C) SEQ ID NOs: 6 and 11;
(D) SEQ ID NOs: 7 and 9, respectively;
(E) SEQ ID NOs: 7 and 10, respectively;
(F) SEQ ID NOs: 7 and 11, respectively;
(G) SEQ ID NOs: 8 and 9, respectively;
The antibody or antigen-binding fragment thereof comprising (h) a heavy chain variable region and a light chain variable region containing the amino acid sequences of SEQ ID NOs: 8 and 11, respectively; or (i).
（ａ）それぞれ配列番号１６及び１９；
（ｂ）それぞれ配列番号１６及び３０；
（ｃ）それぞれ配列番号１６及び３１；
（ｄ）それぞれ配列番号１７及び１９；
（ｅ）それぞれ配列番号１７及び３０；
（ｆ）それぞれ配列番号１７及び３１；
（ｇ）それぞれ配列番号１８及び１９；
（ｈ）それぞれ配列番号１８及び３０；
（ｉ）それぞれ配列番号１８及び３１；
（ｊ）それぞれ配列番号８９及び１９；
（ｋ）それぞれ配列番号９０及び１９；または
（ｌ）それぞれ配列番号９１及び１９のアミノ酸配列を含む重鎖及び軽鎖を含む、請求項１～３のいずれか１項に記載の抗体またはその抗原結合断片。 The antibody or antigen-binding fragment
(A) SEQ ID NOs: 16 and 19;
(B) SEQ ID NOs: 16 and 30, respectively;
(C) SEQ ID NOs: 16 and 31, respectively;
(D) SEQ ID NOs: 17 and 19, respectively;
(E) SEQ ID NOs: 17 and 30, respectively;
(F) SEQ ID NOs: 17 and 31, respectively;
(G) SEQ ID NOs: 18 and 19, respectively;
(H) SEQ ID NOs: 18 and 30, respectively;
(I) SEQ ID NOs: 18 and 31, respectively;
(J) SEQ ID NOs: 89 and 19;
(K) The antibody or antigen thereof according to any one of claims 1 to 3 , which comprises a heavy chain and a light chain containing the amino acid sequences of SEQ ID NOs: 90 and 19; or (l), respectively. Bonded fragment.
The therapeutic antibody or antigen binding fragment comprises (i) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 54 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 55, or (ii) of SEQ ID NO: 64. The composition or kit according to any one of claims 20 to 27 , comprising a heavy chain variable region comprising an amino acid sequence and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 65.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023206823A JP2024026309A (en) | 2018-03-02 | 2023-12-07 | B7-h4 antibodies and methods of use thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862637740P | 2018-03-02 | 2018-03-02 | |
| US62/637,740 | 2018-03-02 | ||
| PCT/US2019/020189 WO2019169212A1 (en) | 2018-03-02 | 2019-03-01 | B7-h4 antibodies and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023206823A Division JP2024026309A (en) | 2018-03-02 | 2023-12-07 | B7-h4 antibodies and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021516051A JP2021516051A (en) | 2021-07-01 |
| JPWO2019169212A5 true JPWO2019169212A5 (en) | 2022-03-09 |
Family
ID=65763883
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020545621A Pending JP2021516051A (en) | 2018-03-02 | 2019-03-01 | B7-H4 antibody and how to use it |
| JP2023206823A Pending JP2024026309A (en) | 2018-03-02 | 2023-12-07 | B7-h4 antibodies and methods of use thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023206823A Pending JP2024026309A (en) | 2018-03-02 | 2023-12-07 | B7-h4 antibodies and methods of use thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11939383B2 (en) |
| EP (1) | EP3759142A1 (en) |
| JP (2) | JP2021516051A (en) |
| KR (1) | KR20200144094A (en) |
| CN (1) | CN111971308A (en) |
| AU (1) | AU2019228600A1 (en) |
| BR (1) | BR112020017925A2 (en) |
| CA (1) | CA3091801A1 (en) |
| EA (1) | EA202091810A1 (en) |
| IL (1) | IL276790A (en) |
| MA (1) | MA52416A (en) |
| MX (1) | MX2020009037A (en) |
| SG (1) | SG11202008105RA (en) |
| WO (1) | WO2019169212A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11306144B2 (en) | 2017-08-25 | 2022-04-19 | Five Prime Therapeutics, Inc. | B7-H4 antibodies and methods of use thereof |
| KR20200119846A (en) * | 2018-02-11 | 2020-10-20 | 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 | Anti-B7 H4 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof |
| WO2019165077A1 (en) * | 2018-02-21 | 2019-08-29 | Five Prime Therapeutics, Inc. | B7-h4 antibody formulations |
| SG11202008105RA (en) | 2018-03-02 | 2020-09-29 | Five Prime Therapeutics Inc | B7-h4 antibodies and methods of use thereof |
| EP4313312A1 (en) | 2021-03-26 | 2024-02-07 | Innate Pharma | Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging |
| BR112023025331A2 (en) | 2021-06-09 | 2024-02-27 | Innate Pharma | MULTI-SPECIFIC PROTEIN, PHARMACEUTICAL COMPOSITION, RECOMBINANT CELL, NUCLEIC ACID OR NUCLEIC ACID SET, USE OF A PROTEIN OR COMPOSITION, METHODS OR USE |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| US20230117205A1 (en) * | 2021-09-30 | 2023-04-20 | Seagen Inc. | B7-h4 antibody-drug conjugates for the treatment of cancer |
Family Cites Families (184)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (en) | 1970-11-10 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| EP0216846B2 (en) | 1985-04-01 | 1995-04-26 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US4938948A (en) | 1985-10-07 | 1990-07-03 | Cetus Corporation | Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| JP3101690B2 (en) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | Modifications of or for denatured antibodies |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| JP3771253B2 (en) | 1988-09-02 | 2006-04-26 | ダイアックス コープ． | Generation and selection of novel binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US7328387B2 (en) | 2004-12-10 | 2008-02-05 | Texas Instruments Incorporated | Addressable tap domain selection circuit with selectable ⅗ pin interface |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| JPH049249A (en) | 1990-04-27 | 1992-01-14 | Kusuda:Kk | Facing agent spraying machine |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| DK0564531T3 (en) | 1990-12-03 | 1998-09-28 | Genentech Inc | Enrichment procedure for variant proteins with altered binding properties |
| CA2108147C (en) | 1991-04-10 | 2009-01-06 | Angray Kang | Heterodimeric receptor libraries using phagemids |
| MX9204374A (en) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | RECOMBINANT ANTIBODY AND METHOD FOR ITS PRODUCTION. |
| US5885793A (en) | 1991-12-02 | 1999-03-23 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
| GB9206422D0 (en) | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| JPH08511420A (en) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | Body |
| EP0733070A1 (en) | 1993-12-08 | 1996-09-25 | Genzyme Corporation | Process for generating specific antibodies |
| DK1231268T3 (en) | 1994-01-31 | 2005-11-21 | Univ Boston | Polyclonal antibody libraries |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
| JP2978435B2 (en) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | Method for producing acryloxypropyl silane |
| DE69731289D1 (en) | 1996-03-18 | 2004-11-25 | Univ Texas | IMMUNGLOBULIN-LIKE DOMAIN WITH INCREASED HALF-VALUE TIMES |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US20060223077A1 (en) | 1997-06-06 | 2006-10-05 | Human Genome Sciences, Inc. | 207 human secreted proteins |
| US20030181692A1 (en) | 1997-06-06 | 2003-09-25 | Jian Ni | 207 human secreted proteins |
| US20030060612A1 (en) | 1997-10-28 | 2003-03-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| PT1071700E (en) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| US6914130B2 (en) | 1998-06-17 | 2005-07-05 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| SE9804180L (en) | 1998-12-03 | 2000-01-24 | Scania Cv Ab | Device for ventilating a space in a vehicle |
| US6468546B1 (en) | 1998-12-17 | 2002-10-22 | Corixa Corporation | Compositions and methods for therapy and diagnosis of ovarian cancer |
| US20020119158A1 (en) | 1998-12-17 | 2002-08-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
| US6962980B2 (en) | 1999-09-24 | 2005-11-08 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
| US7888477B2 (en) | 1998-12-17 | 2011-02-15 | Corixa Corporation | Ovarian cancer-associated antibodies and kits |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PL209786B1 (en) | 1999-01-15 | 2011-10-31 | Genentech Inc | Variant of mother polypeptide containing Fc region, polypeptide containing variant of Fc region with altered affinity of Fc gamma receptor binding (Fc R), polypeptide containing variant of Fc region with altered affinity of Fc gamma neonatal receptor binding (Fc Rn), composition, isolated nucleic acid, vector, host cell, method for obtaining polypeptide variant, the use thereof and method for obtaining region Fc variant |
| ES2569919T3 (en) | 1999-04-09 | 2016-05-13 | Kyowa Hakko Kirin Co., Ltd. | Procedure to control the activity of an immunofunctional molecule |
| WO2001029246A1 (en) | 1999-10-19 | 2001-04-26 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing polypeptide |
| CA2392510A1 (en) | 1999-11-30 | 2001-06-07 | Corixa Corporation | Compositions and methods for therapy and diagnosis of breast cancer |
| US20020146727A1 (en) | 1999-11-30 | 2002-10-10 | Dillon Davin C. | Compositions and methods for the therapy and diagnosis of breast cancer |
| US20040142361A1 (en) | 1999-11-30 | 2004-07-22 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| AU2001245308A1 (en) | 2000-02-24 | 2001-09-03 | Human Genome Sciences, Inc. | 207 human secreted proteins |
| EP1297172B1 (en) | 2000-06-28 | 2005-11-09 | Glycofi, Inc. | Methods for producing modified glycoproteins |
| CA2406649A1 (en) | 2000-06-30 | 2002-01-10 | Human Genome Sciences, Inc. | B7-like polynucleotides, polypeptides, and antibodies |
| AU2001283507A1 (en) | 2000-07-27 | 2002-02-13 | Mayo Foundation For Medical Education And Research | B7-h3 and b7-h4, novel immunoregulatory molecules |
| EP1311674A2 (en) | 2000-08-24 | 2003-05-21 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| EP1311662A2 (en) | 2000-08-24 | 2003-05-21 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| CA2785941C (en) | 2000-10-06 | 2017-01-10 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| CA2424977C (en) | 2000-10-06 | 2008-03-18 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| EP2357187A1 (en) | 2000-12-12 | 2011-08-17 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| AU2002258518A1 (en) | 2001-03-14 | 2002-09-24 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer |
| US7705120B2 (en) | 2001-06-21 | 2010-04-27 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| IL166244A0 (en) | 2001-07-12 | 2006-01-15 | Jefferson Foote | Super humanized antibodies |
| NZ603111A (en) | 2001-08-03 | 2014-05-30 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| WO2005062788A2 (en) | 2003-12-22 | 2005-07-14 | Avalon Pharmaceuticals, Inc. | Prostate specific proteins expressed in cancer and methods of use thereof |
| WO2005035724A2 (en) | 2003-10-08 | 2005-04-21 | Avalon Pharmaceuticals, Inc | Cancer-linked genes as targets for chemotherapy |
| WO2003101400A2 (en) | 2002-06-04 | 2003-12-11 | Avalon Pharmaceuticals, Inc. | Cancer-linked gene as target for chemotherapy |
| WO2003097802A2 (en) | 2002-05-16 | 2003-11-27 | Avalon Pharmaceuticals | Cancer-linked gene as target for chemotherapy |
| US20030219382A1 (en) | 2002-03-06 | 2003-11-27 | Young Paul E. | Cancer-linked gene as target for chemotherapy |
| NZ534880A (en) | 2002-03-19 | 2008-04-30 | Plant Res Int Bv | Optimizing glycan processing in plants |
| US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
| CA2485983A1 (en) | 2002-05-15 | 2003-11-27 | Avalon Pharmaceuticals | Cancer-linked gene as target for chemotherapy |
| CA2488629A1 (en) | 2002-06-07 | 2003-12-18 | Avalon Pharmaceuticals, Inc | Cancer-linked gene as target for chemotherapy |
| EP1572712A4 (en) | 2002-06-11 | 2007-07-04 | Avalon Pharmaceuticals | Cancer-linked gene as target for chemotherapy |
| CA2489803A1 (en) | 2002-06-20 | 2003-12-31 | The Regents Of The University Of California | Compositions and methods for modulating lymphocyte activity |
| JP2006511222A (en) | 2002-12-20 | 2006-04-06 | アバロン ファーマシューティカルズ，インコーポレイテッド | Breast-specific protein expressed in cancer and uses thereof |
| EP1587921B1 (en) | 2003-01-22 | 2010-07-28 | GlycArt Biotechnology AG | Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function |
| ATE516047T1 (en) | 2003-05-09 | 2011-07-15 | Diadexus Inc | OVR110 ANTIBODY COMPOSITIONS AND METHODS OF USE |
| US20050163772A1 (en) | 2003-06-16 | 2005-07-28 | University Of Washington | B7S1: an immune modulator |
| WO2005052121A2 (en) | 2003-11-21 | 2005-06-09 | Archemix Corp. | Multivalent aptamers |
| JO3000B1 (en) | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
| US20090136490A1 (en) | 2004-11-10 | 2009-05-28 | Diadexus, Inc. | Ovr110 antibody compositions and methods for use |
| US8188232B1 (en) | 2004-11-15 | 2012-05-29 | Washington University In St. Louis | Compositions and methods for modulating lymphocyte activity |
| EP1841793B1 (en) | 2005-01-07 | 2010-03-31 | Diadexus, Inc. | Ovr110 antibody compositions and methods of use |
| JP2008532516A (en) | 2005-03-11 | 2008-08-21 | ジェネンテック・インコーポレーテッド | Gene disruption, composition, and related methods |
| EP3058955B1 (en) | 2005-03-24 | 2019-05-29 | Millennium Pharmaceuticals, Inc. | Antibodies that bind ov064 and methods of use therefor |
| US8759490B2 (en) | 2005-03-24 | 2014-06-24 | Millennium Pharamaceuticals, Inc. | Antibodies that bind OV064 and methods of use therefor |
| PT1866339E (en) | 2005-03-25 | 2013-09-03 | Gitr Inc | Gitr binding molecules and uses therefor |
| US20090118175A1 (en) | 2005-05-06 | 2009-05-07 | Macina Roberto A | Compositions and Methods for Detection, Prognosis and Treatment of Breast Cancer |
| EP1888649A2 (en) | 2005-05-09 | 2008-02-20 | GlycArt Biotechnology AG | Antigen binding molecules having modified fc regions and altered binding to fc receptors |
| HUE030877T2 (en) | 2005-06-08 | 2017-06-28 | Dana Farber Cancer Inst Inc | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1)pathway |
| JP2006345852A (en) | 2005-06-16 | 2006-12-28 | Virxsys Corp | Antibody conjugate |
| AU2006265108C1 (en) | 2005-07-01 | 2013-01-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
| CA2630483C (en) | 2005-12-08 | 2015-05-19 | Medarex, Inc. | Human monoclonal antibodies to o8e |
| US20090215084A1 (en) | 2006-01-05 | 2009-08-27 | Mayo Foundation For Medical Education And Research | B7-h1 and b7-h4 in cancer |
| BRPI0707290A2 (en) | 2006-01-17 | 2011-08-16 | Biolex Therapeutics Inc | compositions and methods for humanization and optimization of n-glycans in plants |
| GEP20135917B (en) | 2006-03-17 | 2013-09-10 | Biogen Idec Inc | Stabilized polypeptide compositions |
| US9121853B2 (en) * | 2006-03-20 | 2015-09-01 | Mayo Foundation For Medical Education And Research | B7-H4 expression on tumor vasculature |
| US7846724B2 (en) | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
| WO2007124361A2 (en) | 2006-04-20 | 2007-11-01 | Mayo Foundation For Medical Education And Research | Soluble b7-h1 |
| WO2008051930A2 (en) | 2006-10-23 | 2008-05-02 | Acco Brands Usa Llc | Security apparatus |
| CA2670696A1 (en) | 2006-11-27 | 2008-06-05 | Diadexus, Inc. | Ovr110 antibody compositions and methods of use |
| EP2102241A2 (en) | 2006-12-15 | 2009-09-23 | Ablynx N.V. | Amino acid sequences that modulate the interaction between cells of the immune system |
| WO2008083228A2 (en) | 2006-12-27 | 2008-07-10 | The Johns Hopkins University | Compositions and methods for treating inflammation and auto-immune diseases |
| US20090227533A1 (en) | 2007-06-08 | 2009-09-10 | Bader Andreas G | miR-34 Regulated Genes and Pathways as Targets for Therapeutic Intervention |
| CA2693677C (en) | 2007-07-12 | 2018-02-13 | Tolerx, Inc. | Combination therapies employing gitr binding molecules |
| TWI595005B (en) | 2007-08-21 | 2017-08-11 | 安健股份有限公司 | Human c-fms antigen binding proteins |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| BRPI0816785A2 (en) | 2007-09-14 | 2017-05-02 | Adimab Inc | rationally designed synthetic antibody libraries, and uses thereof |
| AR069747A1 (en) | 2007-11-30 | 2010-02-17 | Medarex Inc | ANTI-B7H4 MONOCLONAL ANTIBODY CONJUGATE - PHARMACO AND METHODS OF USE |
| US20110020325A1 (en) | 2008-02-29 | 2011-01-27 | Kwon Eugene D | Methods for reducing granulomatous inflammation |
| AU2010282340B2 (en) | 2009-08-13 | 2016-12-22 | The Johns Hopkins University | Methods of modulating immune function |
| CN102741279A (en) | 2009-08-31 | 2012-10-17 | 艾普利穆恩公司 | B7-h4 fusion proteins and methods of use thereof |
| AU2010289677B2 (en) | 2009-09-03 | 2014-07-31 | Merck Sharp & Dohme Llc | Anti-GITR antibodies |
| EP2542588A1 (en) | 2010-03-05 | 2013-01-09 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r and uses thereof |
| AR080698A1 (en) | 2010-04-01 | 2012-05-02 | Imclone Llc | ANTIBODY OR FRAGMENT OF THE SAME THAT SPECIFICALLY LINKS THE VARIOUS OF HUMAN CSF -1R, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER AND METHOD TO DETERMINE IF A BASED SUBJECT MATTER AND |
| EA036336B1 (en) | 2010-05-04 | 2020-10-28 | Файв Прайм Терапьютикс, Инк. | Antibodies that bind csf1r |
| US20120014947A1 (en) | 2010-07-16 | 2012-01-19 | The University Of Chicago | Methods and compositions to reduce liver damage associated with conditions or therapies that affect the immune system |
| EP2593594B1 (en) | 2010-07-16 | 2017-09-27 | Adimab, LLC | Antibody libraries |
| PT2691417T (en) | 2011-03-29 | 2018-10-31 | Roche Glycart Ag | Antibody fc variants |
| PL2699264T3 (en) | 2011-04-20 | 2018-08-31 | Medimmune, Llc | Antibodies and other molecules that bind b7-h1 and pd-1 |
| WO2012145568A1 (en) | 2011-04-21 | 2012-10-26 | Albert Einstein College Of Medicine Of Yeshiva University | Antibodies to human b7x for treatment of metastatic cancer |
| KR102030987B1 (en) | 2011-04-25 | 2019-11-11 | 다이이찌 산쿄 가부시키가이샤 | Anti-b7-h3 antibody |
| US8852599B2 (en) | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
| EP2756094B1 (en) * | 2011-08-15 | 2017-12-27 | Medlmmune, LLC | Anti-b7-h4 antibodies and their uses |
| ES2861435T3 (en) | 2011-11-03 | 2021-10-06 | Univ Pennsylvania | Specific compositions of isolated B7-H4 and methods of using them |
| AU2012344260B2 (en) | 2011-11-28 | 2017-09-07 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
| JP2016509582A (en) | 2012-12-19 | 2016-03-31 | アンプリミューン， インコーポレイテッド | Anti-human B7-H4 antibody and use thereof |
| RU2691428C2 (en) | 2012-12-21 | 2019-06-13 | МЕДИММЬЮН, ЭлЭлСи | Antibodies to h7cr |
| PE20151672A1 (en) | 2013-03-14 | 2015-11-27 | Genentech Inc | ANTI-B7-H4 ANTIBODIES AND IMMUNOCONJUGATES |
| US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
| WO2014186798A1 (en) | 2013-05-17 | 2014-11-20 | Amplimmune, Inc. | Receptors for b7-h4 |
| LT3027651T (en) | 2013-08-01 | 2019-04-10 | Five Prime Therapeutics, Inc. | Afucosylated anti-fgfr2iiib antibodies |
| RU2016107426A (en) | 2013-08-02 | 2017-09-07 | Адуро Байотек Холдингс, Юроуп Б.В. | COMBINING CD27 AGONISTS AND INHIBITING IMMUNE CONTROL POINTS TO STIMULATE IMMUNITY |
| TW201605896A (en) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | GITR antigen binding proteins |
| CN105828834A (en) | 2013-11-05 | 2016-08-03 | 同源生物服务股份有限公司 | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
| US10689432B2 (en) | 2013-12-18 | 2020-06-23 | Albert Einstein College Of Medicine | B7X and its derivatives for treating and preventing cardiovascular disease |
| US20170044268A1 (en) | 2013-12-23 | 2017-02-16 | OncoMed Pharmaceuticals | Immunotherapy with Binding Agents |
| WO2015112534A2 (en) | 2014-01-21 | 2015-07-30 | Medimmune, Llc | Compositions and methods for modulating and redirecting immune responses |
| AU2015237864B2 (en) | 2014-03-24 | 2020-12-03 | Cancer Research Technology Limited | Modified antibodies containing modified IgG2 domains which elicit agonist or antagonistic properties and use thereof |
| CN103981150B (en) * | 2014-03-28 | 2016-06-01 | 苏州大学 | Anti-human B7-H4 monoclonal antibody and Synthesis and applications thereof |
| AR101848A1 (en) | 2014-09-12 | 2017-01-18 | Genentech Inc | ANTI-B7-H4 AND IMMUNOCATE PLAYERS |
| EP3207063B1 (en) | 2014-10-17 | 2020-12-02 | Dana-Farber Cancer Institute, Inc. | Methods for identification t-cell exhaustion using cd39 biomarkers and modulators |
| WO2016070001A1 (en) | 2014-10-31 | 2016-05-06 | Jounce Therapeutics, Inc. | Methods of treating conditions with antibodies that bind b7-h4 |
| US20180118831A1 (en) | 2015-03-27 | 2018-05-03 | University Of Southern California | Car t-cells for the treatment of b7-h4 expressing solid tumors |
| PT3283107T (en) | 2015-04-17 | 2020-08-31 | Bristol Myers Squibb Co | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
| CN107969128A (en) | 2015-04-17 | 2018-04-27 | 高山免疫科学股份有限公司 | Immune modulator with adjustable affinity |
| CN107921018A (en) | 2015-06-11 | 2018-04-17 | 生态有限公司 | Drug regimen and its application |
| IL257030B2 (en) | 2015-07-23 | 2023-03-01 | Inhibrx Inc | Multivalent and multispecific gitr-binding fusion proteins, compositions comprising same and uses thereof |
| JO3736B1 (en) | 2015-07-30 | 2021-01-31 | Macrogenics Inc | PD-1-Binding Molecules and Methods of Use Thereof |
| CN108513576A (en) | 2015-09-14 | 2018-09-07 | 高山免疫科学股份有限公司 | Adjustable variant immunoglobulin superfamily structural domain and engineered cell therapy |
| WO2017058754A1 (en) | 2015-09-28 | 2017-04-06 | Celgene Corporation | Combination therapy for treatment of hematological cancers and solid tumors |
| KR20180069903A (en) | 2015-11-02 | 2018-06-25 | 파이브 프라임 테라퓨틱스, 인크. | CD80 extracellular domain polypeptides and their use in the treatment of cancer |
| AU2016369537B2 (en) | 2015-12-17 | 2024-03-14 | Novartis Ag | Antibody molecules to PD-1 and uses thereof |
| WO2017129790A1 (en) | 2016-01-28 | 2017-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of cancer |
| US20190048094A1 (en) | 2016-02-24 | 2019-02-14 | Oncomed Pharmaceuticals, Inc. | Redirecting immune responses |
| HRP20240052T1 (en) | 2016-03-04 | 2024-03-29 | Io Biotech Aps | Combination therapy against cancer |
| US10875919B2 (en) | 2016-04-26 | 2020-12-29 | Alector Llc | Chimeric receptors and methods of use thereof |
| EA201892587A1 (en) | 2016-05-20 | 2019-04-30 | Биохэйвен Фармасьютикал Холдинг Компани Лтд. | USE OF GLUTAMAT-MODULATING AGENTS TOGETHER WITH IMMUNOTHERAPY FOR CANCER TREATMENT |
| IL265274B2 (en) | 2016-09-16 | 2023-11-01 | Bionomics Ltd | Combination of anti-lgr5 antibody and antibody inhibitor of pd-1 for tumour treatment |
| US10042000B2 (en) | 2016-10-13 | 2018-08-07 | Stmicroelectronics (Grenoble 2) Sas | Method and apparatus for high frequency analog-to-digital conversion |
| CA3040296A1 (en) | 2016-10-20 | 2018-04-26 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
| GB201618291D0 (en) | 2016-10-28 | 2016-12-14 | Bergen Teknologioverf�Ring As | Novel immunotherapeutic treatments for tumours |
| MX2019005772A (en) | 2016-11-23 | 2019-10-02 | Bioverativ Therapeutics Inc | Mono- and bispecific antibodies binding to coagulation factor ix and coagulation factor x. |
| CN110300599A (en) | 2016-12-07 | 2019-10-01 | 艾吉纳斯公司 | Antibody and its application method |
| ES2963226T3 (en) | 2016-12-07 | 2024-03-26 | Agenus Inc | ANTI-CTLA-4 antibodies and methods of their use |
| CN107299085B (en) * | 2017-05-26 | 2020-09-29 | 广东医科大学 | Hybridoma cell strain secreting anti-human B7-H4 extracellular monoclonal antibody, anti-human B7-H4 monoclonal antibody and application of anti-human B7-H4 extracellular monoclonal antibody |
| US11306144B2 (en) | 2017-08-25 | 2022-04-19 | Five Prime Therapeutics, Inc. | B7-H4 antibodies and methods of use thereof |
| KR20200123169A (en) | 2018-02-21 | 2020-10-28 | 파이브 프라임 테라퓨틱스, 인크. | B7-H4 antibody dosing regimen |
| WO2019165077A1 (en) | 2018-02-21 | 2019-08-29 | Five Prime Therapeutics, Inc. | B7-h4 antibody formulations |
| SG11202008105RA (en) | 2018-03-02 | 2020-09-29 | Five Prime Therapeutics Inc | B7-h4 antibodies and methods of use thereof |
| SG11202103153VA (en) | 2018-10-15 | 2021-04-29 | Five Prime Therapeutics Inc | Combination therapy for cancer |
-
2019
- 2019-03-01 SG SG11202008105RA patent/SG11202008105RA/en unknown
- 2019-03-01 CN CN201980025931.8A patent/CN111971308A/en active Pending
- 2019-03-01 MA MA052416A patent/MA52416A/en unknown
- 2019-03-01 AU AU2019228600A patent/AU2019228600A1/en active Pending
- 2019-03-01 BR BR112020017925-6A patent/BR112020017925A2/en unknown
- 2019-03-01 EP EP19710951.5A patent/EP3759142A1/en not_active Withdrawn
- 2019-03-01 EA EA202091810A patent/EA202091810A1/en unknown
- 2019-03-01 CA CA3091801A patent/CA3091801A1/en active Pending
- 2019-03-01 JP JP2020545621A patent/JP2021516051A/en active Pending
- 2019-03-01 KR KR1020207028346A patent/KR20200144094A/en active Search and Examination
- 2019-03-01 MX MX2020009037A patent/MX2020009037A/en unknown
- 2019-03-01 WO PCT/US2019/020189 patent/WO2019169212A1/en active Application Filing
-
2020
- 2020-08-18 IL IL276790A patent/IL276790A/en unknown
- 2020-08-28 US US17/006,670 patent/US11939383B2/en active Active
-
2023
- 2023-12-07 JP JP2023206823A patent/JP2024026309A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015172045A5 (en) | ||
| JP2020530272A5 (en) | ||
| JP2020534830A5 (en) | ||
| JP2013535191A5 (en) | ||
| JP2020533016A5 (en) | ||
| US10247739B2 (en) | Method for immunological measurement using a hapten and antibody binding to the hapten as reference antibody and device for immunological measurement using the reference antibody | |
| JP2017524362A5 (en) | ||
| JP2017521054A5 (en) | ||
| JPWO2019169212A5 (en) | ||
| CN108659131B (en) | anti-CEACAM-5 single-domain antibody and application thereof | |
| JP2020518243A5 (en) | ||
| CN116829600A (en) | CD 5-targeting fully human antibodies | |
| JPWO2021048725A5 (en) | ||
| US11009507B2 (en) | Methods and diagnostics for cancer detection and treatment monitoring | |
| JP2024001073A5 (en) | ||
| JP2019513004A5 (en) | ||
| CN113880948B (en) | anti-CA 724 antibody or antigen-binding fragment thereof, and preparation method and application thereof | |
| WO2018135653A1 (en) | Anti-epha2 antibody and immunological detection of epha2 using same | |
| JPWO2019175885A5 (en) | ||
| JP2020515286A5 (en) | ||
| JPWO2020227538A5 (en) | ||
| CN110579610A (en) | Kit for detecting V-domain immunosuppressive factor activated by T cells | |
| KR20200002190A (en) | Anti-Sphingosine-1-Phosphate agent, production method, and uses thereof | |
| KR20180041466A (en) | Antibody specifically binding to core fucosylated alpha-fetoprotein and use thereof | |
| JPWO2021133723A5 (en) |